Target intelligence / Profile preview

MMS22 like, DNA repair protein (MMS22L)

Target
MMS22L
Molecular classification
DNA repair regulator, Genome caretaker, Homologous recombination factor, Chromatin-associated protein
01

Overview

MMS22L (MMS22 like, DNA repair protein) encodes a DNA repair protein that forms a critical complex with TONSL (tonsoku-like, DNA repair protein), known as the MMS22L-TONSL complex. This complex functions as a genome caretaker and promotes homologous recombination-mediated repair of DNA double-strand breaks and stalled or collapsed replication forks, primarily by facilitating loading and assembly of the RAD51 recombinase on single-stranded DNA. MMS22L is essential for protecting DNA during the replication process and maintaining genome integrity, interacting with RPA-coated ssDNA, RAD51, and potentially NFKBIL2 for chromatin regulation. MMS22L is overexpressed in various cancers, underscoring its importance for rapidly dividing tumor cells and identifying it as a promising target for cancer therapy and chemical sensitization. Loss of MMS22L leads to increased endogenous DNA double-strand breaks and heightened sensitivity to DNA replication stress-inducing agents such as camptothecin. No direct small-molecule inhibitors or approved drugs currently target MMS22L directly; its role is primarily elucidated via genetic depletion or inhibition studies. It is not a receptor, enzyme, ion channel, transporter, or transcription factor, but instead acts as a DNA repair regulator—a chromatin-associated DNA repair facilitator.

Other names
Protein MMS22-likeC6orf167dJ39B17.2Methyl methanesulfonate-sensitivity protein 22-like
02

Mechanism of action

Drugs like camptothecin cause replication fork stalling/collapse; MMS22L-TONSL functions to repair these lesions via homologous recombination

03

Biological functions

DNA repairHomologous recombinationReplication fork protectionGenome integrity maintenanceRAD51 filament assembly on ssDNAHistone interaction/chromatin regulation
04

Disease associations

Cancer (overexpressed in lung and esophageal cancers)Spondyloepimetaphyseal Dysplasia, Sponastrime TypeFanconi anemia, Complementation Group A
05

Safety considerations

Therapeutic inhibition may lead to increased genome instability, higher toxicity for rapidly dividing cells (on-target effects in healthy replicating tissues)
06

Interacting drugs

Camptothecin (cell depletion of MMS22L increases sensitivity to camptothecin, a topoisomerase I poison)

1 more in the full profile.

07

Biomarkers

MMS22L expression itself may serve as a biomarker for genome instability or DNA repair pathway activation, particularly in cancer

Beyond the preview

Go deeper on MMS22 like, DNA repair protein (MMS22L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMS22 like, DNA repair protein (MMS22L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call